The Pathology Core is an integral pillar of the MSK Precision Pathology Biobanking Center and provides a comprehensive resource for human tissue-based research that takes advantage of the unique tissue resources available at MSK. The acquisition and banking of human biologic specimens to be used to study causes, detection, prevention, and treatment of cancer have become an indispensible resource for basic and translational cancer researchers throughout MSK. The reliability of molecular data derived from new technology platforms depends on access to an adequate supply of optimally procured, high-quality tissue specimens. The Pathology Core at MSK provides efficient and cost-effective services to facilitate tissue use and to conduct human biospecimen-based experimentation. The Core also serves as a national resource, as evidenced by the over 1,000 samples from multiple tumor types that have been provided to the NCI-funded TCGA initiative, as well as the samples that will be contributed to the NCI?s CPTAC proteogenomics consortium. The Histology Service within the Core facilitates selection of appropriate specimens for tissue analyses and provides the basic services of cutting, dissecting, and staining of fresh-frozen and formalin-fixed, paraffin- embedded tissues. It includes construction of tissue microarray blocks and laser capture microdissection for isolation of pure cell populations and tumor cell enrichment. The Core?s Immunohistochemistry Service provides automated and manual staining using optimized monoclonal and polyclonal antibodies to be used in clinico-pathologic research studies. The service also continuously develops and optimizes protocols for new antibodies and for a variety of sensitive detection systems. The services and collaborative work provided by the Pathology Core have contributed to 1,685 publications of MSK researchers from nine of the 10 Center Programs. Many of these papers were published in leading cancer and general interest journals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084822
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Parker, Patricia A; Banerjee, Smita C; Matasar, Matthew J et al. (2018) Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer 124:4567-4576
Chou, Chun; Li, Ming O (2018) Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer. Cancer Immunol Res 6:372-377
Scope, A; Dusza, S W; Pellacani, G et al. (2018) Accuracy of tele-consultation on management decisions of lesions suspect for melanoma using reflectance confocal microscopy as a stand-alone diagnostic tool. J Eur Acad Dermatol Venereol :
Baradaran, Rozbeh; Wang, Chongyuan; Siliciano, Andrew Francis et al. (2018) Cryo-EM structures of fungal and metazoan mitochondrial calcium uniporters. Nature 559:580-584
Patel, Sunil V; Yu, David; Elsolh, Basheer et al. (2018) Assessment of Conflicts of Interest in Robotic Surgical Studies: Validating Author's Declarations With the Open Payments Database. Ann Surg 268:86-92
Wolner, Z J; Marghoob, A A; Pulitzer, M P et al. (2018) A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol 178:265-269
Corrias, Giuseppe; Monti, Serena; Mannelli, Lorenzo (2018) Right Upper Quadrant Pain in a 47-Year-Old Woman. Gastroenterology 154:e11-e12
Hu, Zishuo I; Shia, Jinru; Stadler, Zsofia K et al. (2018) Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res 24:1326-1336
Connors, Joseph M; Jurczak, Wojciech; Straus, David J et al. (2018) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344
Reznik, Ed; Luna, Augustin; Aksoy, Bülent Arman et al. (2018) A Landscape of Metabolic Variation across Tumor Types. Cell Syst 6:301-313.e3

Showing the most recent 10 out of 8799 publications